How Does Vildagliptin Affect the Heart in Patients With Reduced Ejection Fraction? How Does Vildagliptin Affect the Heart in Patients With Reduced Ejection Fraction?

The oral anti-hyperglycemic agent vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, does not appear to worsen ventricular systolic function in patients with type 2 diabetes and heart failure with reduced ejection fraction (HFrEF), according to results from a 52-week randomized trial.Reuters Health Information
Source: Medscape Radiology Headlines - Category: Radiology Tags: Internal Medicine News Source Type: news